Results 71 to 80 of about 39,435 (253)
Fibrilpaint: A Class of Amyloid‐Targeting Peptides
Chemistry – A European Journal, EarlyView.FibrilPaints are modular peptides engineered to recognize amyloid fibrils. By systematically varying charge, sequence, and termini, their binding behavior can be tuned while retaining recognition. Successful binding ″paints″ fibrils for visualization and opens routes toward targeted degradation and diagnostic applications.
Júlia Aragonès Pedrola +8 more
wiley +1 more source
NeurologíaResumen: Introducción: La enfermedad de Huntington (EH) es un trastorno neurodegenerativo y hereditario. Gracias al diagnóstico predictivo se han descrito características clínicas incipientes en la fase prodrómica.
F. Paz-Rodríguez +6 more
doaj +1 more source
Huntington’s disease: Managing neuropsychiatric symptoms in Huntington’s disease
Australasian Psychiatry, 2018 Objectives: This clinical update review focuses on the management of the neuropsychiatric manifestations of Huntington’s disease (HD). The review highlights current issues regarding pharmacological and non-pharmacological treatment, putative therapeutics and recent relevant research findings in this area.
Samantha M Loi +3 more
openaire +3 more sources
Genetic epilepsies with myoclonic seizures: Mechanisms and syndromes
Epilepsia Open, EarlyView.Abstract Genetic epilepsy with myoclonic seizures encompasses a heterogeneous spectrum of conditions, ranging from benign and self‐limiting forms to severe, progressive disorders. While their causes are diverse, a significant proportion stems from genetic abnormalities.
Antonietta Coppola +3 more
wiley +1 more source
Pediatric Neurology Briefs, 1993 The clinical manifestations, differential diagnosis, and treatment of benign hereditary chorea (BHC) are reviewed from the Indiana University and University of Minnesota Medical Schools.
J Gordon Millichap
doaj +1 more source
Precision therapies for genetic epilepsies in 2025: Promises and pitfalls
Epilepsia Open, EarlyView.Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang +3 more
wiley +1 more source
The achievement and prospect of deep brain stimulation for the treatment of movement disorders
Chinese Journal of Contemporary Neurology and Neurosurgery, 2020 Deep brain stimulation (DBS) was first used in the treatment of essential tremor in 1987, and later used in the treatment of advanced Parkinson's disease (PD), drug⁃refractory dystonia, other types of tremor and Tourette's syndrome, which can reduce the ...
Chao⁃shi NIU, Chi XIONG
doaj
Journal of Mazandaran University of Medical Sciences, 2021 Global prevalence of neurological disorders such as Parkinson's disease, Alzheimer's disease, epilepsy, and multiple sclerosis is steadily increasing, but, there is still no effective delivery system to deliver therapeutic amounts of drug into the ...
Sara Assadpour +2 more
doaj
International Journal of Cancer, EarlyView.ABSTRACT Cancer survivors frequently experience cancer‐related cognitive impairment (CRCI), but the contributions of different anti‐cancer therapies remain unclear. Patients with breast or gynaecological cancer were recruited before any anti‐cancer treatment.
Qiqi Lei +5 more
wiley +1 more source
Clostridium sporogenes bacteremia in an immunocompetent patient
IDCases, 2019 Of the 200 Clostridium spp. known to exist, approximately 30 have been associated with human disease. Commonly found in soil, marine sediment and mammalian intestinal tracts, these gram-positive bacilli are known to cause infections ranging from ...
Waiel Abusnina +4 more
doaj +1 more source